An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease
Phase of Trial: Phase IV
Latest Information Update: 16 May 2016
At a glance
- Drugs Ticagrelor (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 01 Apr 2016 Results published in the British Journal of Clinical Pharmacology
- 30 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.